These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16439608)

  • 21. Hepatorenal Tyrosinemia in Mexico: A Call to Action.
    Ibarra-González I; Ridaura-Sanz C; Fernández-Lainez C; Guillén-López S; Belmont-Martínez L; Vela-Amieva M
    Adv Exp Med Biol; 2017; 959():147-156. PubMed ID: 28755193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J; Wibrand F; Lund AM; Christensen M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of succinylacetone in urine of hepatorenal tyrosinemia patients by HPLC with fluorescence detection.
    Al-Dirbashi OY; Jacob M; Al-Ahaidib LY; Al-Qahtani K; Rahbeeni Z; Al-Owain M; Rashed MS
    Clin Chim Acta; 2006 Mar; 365(1-2):243-8. PubMed ID: 16243307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory monitoring of patients with hereditary tyrosinemia type I.
    Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
    Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newborn screening for Tyr-I: two years' experience of the New York State program.
    Morrissey MA; Sunny S; Fahim A; Lubowski C; Caggana M
    Mol Genet Metab; 2011 Jun; 103(2):191-2. PubMed ID: 21441051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters.
    Chace DH; Lim T; Hansen CR; De Jesus VR; Hannon WH
    Clin Chim Acta; 2009 Sep; 407(1-2):6-9. PubMed ID: 19545553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of factors influencing accuracy in the analysis of succinylacetone in dried blood spots.
    Peng M; Liu L; Peng L
    Clin Chim Acta; 2012 Aug; 413(15-16):1265-9. PubMed ID: 22522056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process.
    Dhillon KS; Bhandal AS; Aznar CP; Lorey FW; Neogi P
    Clin Chim Acta; 2011 May; 412(11-12):873-9. PubMed ID: 21216241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of succinylacetone assays and their associated proficiency testing outcomes.
    Adam BW; Hall EM; Meredith NK; Lim TH; Haynes CA; De Jesus VR; Hannon WH
    Clin Biochem; 2012 Dec; 45(18):1658-63. PubMed ID: 22906829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
    Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosinemia type 1: an overview of nursing care.
    Barnby E
    Pediatr Nurs; 2014; 40(2):61-8, 90. PubMed ID: 24941508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update.
    Giguère Y; Berthier MT
    Adv Exp Med Biol; 2017; 959():139-146. PubMed ID: 28755192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.
    Grenier A; Lescault A; Laberge C; Gagné R; Mamer O
    Clin Chim Acta; 1982 Aug; 123(1-2):93-9. PubMed ID: 7116642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A GC/MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: an analytical tool for tyrosinemia type I.
    Cyr D; Giguère R; Villain G; Lemieux B; Drouin R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):24-9. PubMed ID: 16414314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA-ESI-MS/MS analysis of dried blood spot extracts for newborn screening.
    Haynes CA; De Jesús VR
    Clin Biochem; 2016 Jan; 49(1-2):161-5. PubMed ID: 26432925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening.
    Das AM; Mayorandan S; Janzen N
    Adv Exp Med Biol; 2017; 959():125-132. PubMed ID: 28755190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical and genetic analysis of a patient with tyrosinemia type I but without elevated succinylacetone].
    Guo L; Jiao B; Liu F
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 May; 36(5):472-476. PubMed ID: 31030436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.
    Varughese B; Madrewar D; Polipalli SK; Kapoor S
    Indian J Clin Biochem; 2022 Jan; 37(1):40-50. PubMed ID: 35125692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing newborn screening for tyrosinemia type I.
    Pass KA; Morrissey M
    Clin Chem; 2008 Apr; 54(4):627-9. PubMed ID: 18375485
    [No Abstract]   [Full Text] [Related]  

  • 40. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
    Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.